|Bid||8.16 x 45900|
|Ask||8.25 x 2200|
|Day's Range||8.17 - 8.21|
|52 Week Range||4.02 - 9.15|
|Beta (5Y Monthly)||2.68|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Good afternoon, everyone, and thank you for joining us today for Supernus Pharmaceuticals' Third Quarter 2021 Financial Results Conference Call. On the call with me today are Supernus' Chief Executive Officer, Jack Khattar; and Chief Financial Officer, Tim Dec. Today's call is being made available via the Investor Relations section of the company's website at ir.supernus.com.
If you want to know who really controls Adamas Pharmaceuticals, Inc. ( NASDAQ:ADMS ), then you'll have to look at the...
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.